Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super‐Response and Remission With Mepolizumab

This study identifies two distinct subgroups of patients with severe eosinophilic asthma who respond differently to mepolizumab. Cluster analysis reveals that patients with a family history of asthma, positive skin prick tests and higher baseline lung function have better treatment outcomes, highlighting the value of personalised treatment strategies.